(Q45388333)

English

Augmentation of alphavirus vector-induced human papilloma virus-specific immune and anti-tumour responses by co-expression of interleukin-12.

scientific article published on 27 November 2008

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Augmentation of alphavirus vector-induced human papilloma virus-specific immune and anti-tumour responses by co-expression of interleukin-12. (English)

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

vector-borne disease

0 references

human papilloma virus

object named as

human papilloma virus

1 reference

based on heuristic

inferred from title

5

object named as

Toos Daemen

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

4

object named as

Jan Wilschut

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

author name string

Annelies Riezebos-Brilman

1

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Joke Regts

2

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Margaret Chen

3

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

language of work or name

0 references

publication date

27 November 2008

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

27

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

701-707

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

The causal relation between human papillomavirus and cervical cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.032

7 January 2021

Human papillomavirus immortalization and transformation functions

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.032

7 January 2021

Cervical cancer vaccines: recent advances in HPV research

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.032

7 January 2021

Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.032

7 January 2021

Human papillomavirus infection in women infected with the human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.032

7 January 2021

Prevention of cervical cancer through papillomavirus vaccination

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.032

7 January 2021

Recombinant alphaviruses as vectors for anti-tumour and anti-microbial immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.032

7 January 2021

Immunization strategy against cervical cancer involving an alphavirus vector expressing high levels of a stable fusion protein of human papillomavirus 16 E6 and E7.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.032

7 January 2021

Eradication of established HPV16-transformed tumours after immunisation with recombinant Semliki Forest virus expressing a fusion protein of E6 and E7.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.032

7 January 2021

Induction of human papilloma virus E6/E7-specific cytotoxic T-lymphocyte activity in immune-tolerant, E6/E7-transgenic mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.032

7 January 2021

A comparative study on the immunotherapeutic efficacy of recombinant Semliki Forest virus and adenovirus vector systems in a murine model for cervical cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.032

7 January 2021

The human papillomavirus E7 protein is able to inhibit the antiviral and anti-growth functions of interferon-alpha

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.032

7 January 2021

Avoiding horror autotoxicus: the importance of dendritic cells in peripheral T cell tolerance

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.032

7 January 2021

Immune evasion in human papillomavirus-associated cervical cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.032

7 January 2021

Gene therapy of cancer with interleukin-12.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.032

7 January 2021

Development of TH1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.032

7 January 2021

Natural killer cell stimulatory factor (interleukin 12 [IL-12]) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.032

7 January 2021

Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.032

7 January 2021

Targeted expression of the E6 and E7 oncogenes of human papillomavirus type 16 in the epidermis of transgenic mice elicits generalized epidermal hyperplasia involving autocrine factors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.032

7 January 2021

Immunotherapy with recombinant SFV-replicons expressing the P815A tumor antigen or IL-12 induces tumor regression.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.032

7 January 2021

Induction of antitumor immunity by vaccination of dendritic cells transfected with MUC1 RNA

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.032

7 January 2021

Transfer of the murine interleukin-12 gene in vivo by a Semliki Forest virus vector induces B16 tumor regression through inhibition of tumor blood vessel formation monitored by Doppler ultrasonography

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.032

7 January 2021

Inhibition of angiogenesis in vivo by interleukin 12.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.032

7 January 2021

Regression of mouse tumours and inhibition of metastases following administration of a Semliki Forest virus vector with enhanced expression of IL-12.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.032

7 January 2021

Semliki forest virus vectors engineered to express higher IL-12 levels induce efficient elimination of murine colon adenocarcinomas

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.032

7 January 2021

IL-12: a promising adjuvant for cancer vaccination

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.032

7 January 2021

Interleukin-12 (IL-12) enhancement of the cellular immune response against human immunodeficiency virus type 1 env antigen in a DNA prime/vaccinia virus boost vaccine regimen is time and dose dependent: suppressive effects of IL-12 boost are mediate

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.032

7 January 2021

Immunization with adenoviral vectors carrying recombinant IL-12 and E7 enhanced the antitumor immunity to human papillomavirus 16-associated tumor

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.032

7 January 2021

A novel mucosal vaccine based on live Lactococci expressing E7 antigen and IL-12 induces systemic and mucosal immune responses and protects mice against human papillomavirus type 16-induced tumors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.032

7 January 2021

Subsets of memory cytotoxic T lymphocytes elicited by vaccination influence the efficiency of secondary expansion in vivo

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.032

7 January 2021

Identifiers

10.1016/J.VACCINE.2008.11.032

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45388333&oldid=2006820861"